J
John S. Abrams
Researcher at Schering-Plough
Publications - 21
Citations - 6841
John S. Abrams is an academic researcher from Schering-Plough. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 17, co-authored 21 publications receiving 6693 citations.
Papers
More filters
Journal ArticleDOI
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
TL;DR: The results indicate that IL-10 has important regulatory effects on immunological and inflammatory responses because of its capacity to downregulate class II MHC expression and to inhibit the production of proinflammatory cytokines by monocytes.
Journal Article
Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones.
X Paliard,R de Waal Malefijt,Hans Yssel,D Blanchard,I Chrétien,John S. Abrams,J E de Vries,Hergen Spits +7 more
TL;DR: The kinetics of the secretion of the three lymphokines was investigated with two CD4+ clones; one (GEO-2) that produced IL-2, IL-4, and IFN-gamma and another (HY640), that produced only IL- 2 and IFn-Gamma.
Journal ArticleDOI
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.
Rosa Bacchetta,M. Bigler,Jean Louis Touraine,Robertson Parkman,Pier-Angelo Tovo,John S. Abrams,R de Waal Malefyt,J E de Vries,Maria Grazia Roncarolo +8 more
TL;DR: Data indicate that high endogenous IL- 10 production is a general phenomenon in SCID patients in whom allogenic stem cell transplantation results in immunologic reconstitution and induction of tolerance.
Journal Article
IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells.
Hans Yssel,R de Waal Malefyt,Maria Grazia Roncarolo,John S. Abrams,Riitta Lahesmaa,Hergen Spits,J. E. De Vries +6 more
TL;DR: It is demonstrated that human IL-10 is produced by Th0, Th1-, and Th2-like CD4+ T cell clones after both Ag-specific and polyclonal activation, indicating a regulatory role for IL- 10 in later phases of the immune response.
Journal Article
Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.
TL;DR: IL-6 is a mediator in lethal E. coli infection, and antagonists of IL-6 may be beneficial therapeutically in life-threatening bacterial infection, according to a mouse model of septic shock.